Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $108.3 million.

  • Angiodynamics' Non-Current Assets fell 680.32% to $108.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $442.3 million, marking a year-over-year decrease of 967.0%. This contributed to the annual value of $111.8 million for FY2025, which is 1012.55% down from last year.
  • Latest data reveals that Angiodynamics reported Non-Current Assets of $108.3 million as of Q4 2025, which was down 680.32% from $109.0 million recorded in Q3 2025.
  • Angiodynamics' Non-Current Assets' 5-year high stood at $436.6 million during Q1 2021, with a 5-year trough of $108.3 million in Q4 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $343.8 million (2023), whereas its average is $282.9 million.
  • As far as peak fluctuations go, Angiodynamics' Non-Current Assets tumbled by 265.19% in 2022, and later tumbled by 6721.93% in 2024.
  • Angiodynamics' Non-Current Assets (Quarter) stood at $421.9 million in 2021, then fell by 5.34% to $399.4 million in 2022, then fell by 21.34% to $314.2 million in 2023, then tumbled by 63.0% to $116.2 million in 2024, then decreased by 6.8% to $108.3 million in 2025.
  • Its Non-Current Assets stands at $108.3 million for Q4 2025, versus $109.0 million for Q3 2025 and $111.8 million for Q2 2025.